Medicus Net Income From Continuing Ops from 2010 to 2024

MDCX Stock  USD 2.75  0.05  1.79%   
Medicus Pharma Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2024. During the period from 2010 to 2024, Medicus Pharma Net Loss regression line of annual values had significance of  0.0005 and arithmetic mean of (1,599,867). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-6.8 M
Current Value
-6.4 M
Quarterly Volatility
2.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Medicus Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medicus Pharma's main balance sheet or income statement drivers, such as Interest Expense of 776.1 K, Selling General Administrative of 3 M or Total Revenue of 0.0, as well as many indicators such as . Medicus financial statements analysis is a perfect complement when working with Medicus Pharma Valuation or Volatility modules.
  
Check out the analysis of Medicus Pharma Correlation against competitors.

Latest Medicus Pharma's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Medicus Pharma Ltd over the last few years. It is Medicus Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Medicus Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Medicus Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(1,599,867)
Coefficient Of Variation(139.19)
Mean Deviation1,592,458
Median(693,760)
Standard Deviation2,226,935
Sample Variance5T
Range6.8M
R-Value(0.79)
Mean Square Error2T
R-Squared0.62
Significance0.0005
Slope(392,513)
Total Sum of Squares69.4T

Medicus Net Income From Continuing Ops History

2024-6.4 M
2023-6.8 M
2022-1.7 M
2018-2.1 M
2017-138.9 K
2016 -5767.0

About Medicus Pharma Financial Statements

Medicus Pharma investors use historical fundamental indicators, such as Medicus Pharma's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Medicus Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-6.8 M-6.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Medicus OTC BB Equity Analysis

When running Medicus Pharma's price analysis, check to measure Medicus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicus Pharma is operating at the current time. Most of Medicus Pharma's value examination focuses on studying past and present price action to predict the probability of Medicus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicus Pharma's price. Additionally, you may evaluate how the addition of Medicus Pharma to your portfolios can decrease your overall portfolio volatility.